The OMNIPREDICT project – Omics and Non-invasive Integration for Predictive Health Assessment – aims to develop an integrated platform for the early prediction of sarcopenia and functional decline in elderly individuals with multimorbidity. The project is based on the integration of three main components: multi-omic biomarkers (genetic, lipidomic, and proteomic), non-invasive sensors for continuous clinical monitoring, and a predictive algorithm based on neural networks.
The scientific activities are structured into two work packages. WP1 is dedicated to the collection of biological samples and the validation of biomarkers associated with the risk of sarcopenia, as well as the identification and integration of non-invasive sensors for the assessment of muscle strength, body composition, and mobility. WP2 involves the development of a prototype neural network capable of integrating multi-omic and functional data to generate personalized predictions of muscle decline risk, tested in a preliminary pilot study on elderly patients.
OMNIPREDICT proposes an innovative approach to predictive medicine, combining advanced molecular analysis, wearable technologies, and artificial intelligence. The platform aims to support early diagnosis and guide personalized interventions, with the ultimate goal of improving patient autonomy and quality of life. The project model is designed to be transferable and adaptable to other clinical contexts, with potential impacts also in terms of healthcare system sustainability and optimization of care resources.
In the initial phase of the OMNIPREDICT project (WP1), which aims to develop an integrated platform for the early prediction of sarcopenia and functional decline, all preparatory activities have been completed. These include the definition of inclusion and exclusion criteria, the preparation of regulatory documentation for the collection of biological samples and sensor-derived data, the establishment of recruitment collaborations, and the procurement of non-invasive sensors for assessing muscle strength, body composition, and mobility.
Patient recruitment has commenced, along with the collection of samples for genetic and lipidomic analyses. However, delays have occurred due to the ongoing evaluation process by the Ethics Committee and limited availability of proteomic materials, which have impeded the comprehensive collection of datasets. To ensure continuity and progress, a preliminary multi-omic analysis has been initiated on an initial cohort of patients from the Delta Center.
Deliverable D1.1 (biomarker validation) has been rescheduled for submission by 01 August 2025. All other planned outputs within WP1 remain on track. Activities under WP2 (development of the predictive algorithm) have not yet been launched, pending completion of the validation and data integration phase.